in vitro News and Research

RSS

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) cells can be destroyed and kept from multiplying by inhibiting the HDL cholesterol receptor SCARB1, according to research from the Perelman School of Medicine at the University of Pennsylvania.

10 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

SARS-CoV-2 variants and their ability to infect mice

A new study published on the bioRxiv* preprint server has conducted in silico studies along with in vitro, in vivo, and in situ observations and indicated the mouse adaptation of SARS-CoV-2.

10 Aug 2021

PTEN nuclear translocation plays a key role in neuronal injury following hypoxia-ischemia

Aging-US published "PTEN nuclear translocation enhances neuronal injury after hypoxia-ischemia via modulation of the nuclear factor-κB signaling pathway" which reported that this study was designed to investigate phosphatase and tensin homolog nuclear translocation and its possible role in rat cortical neuronal damage following oxygen-glucose deprivation in vitro.

9 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

Tiny gel drops for the development of regenerative therapies

Tiny drops that resemble an extracellular matrix can be used to culture cells for delivery into the human body.

9 Aug 2021

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

The spike protein comprises of two subunits: S1 subunit having the receptor-binding domain (RBD) that helps it to bind to the angiotensin-converting enzyme 2 (ACE2), which is present on the cell surface of the host, and the S2 subunit that helps in the fusion of the cellular membrane and the viral membrane.

9 Aug 2021

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

A team of international scientists has recently demonstrated the usefulness of cetylpyridinium chloride-containing mouthwashes in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and reducing the risk of viral transmission. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

Researchers develop new low-cost reproducible system for co-cultivation of cells

Scientists of the MIPT Cell Signaling Regulation Laboratory have developed a new low cost reproducible system for the co-cultivation of cells. This system is based on a polymerized BSA membrane.

8 Aug 2021

Research suggests potential new treatment strategy for phenylketonuria

Researchers at The University of Texas MD Anderson Cancer Center have discovered a critical new factor in regulating phenylalanine metabolism and, therefore, in preventing the inherited metabolic disorder phenylketonuria (PKU).

5 Aug 2021

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States and Canada have described the structural basis and mode of action for two monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2021

Feinstein Institutes awarded $2.9 million NIH funding for polygenic embryo selection studies

Genetic testing and selection of embryos generated from in vitro fertilization have given rise to the controversial “designer baby” debate.

4 Aug 2021

Next-generation CRISPR tools and therapies improved by modified RNA guides

A new type of gene-editing tool, CRISPR-Cas13, has shown promise in RNA targeting. Previous studies have shown the tool as a potential treatment method for viral diseases, including coronavirus disease (COVID-19).

3 Aug 2021

Inhibition of SARS-CoV-2 replication in vitro by Losartan

A new study explores the use of Losartan to provide protection against COVID-19 pathogenesis.

3 Aug 2021

“Sybodies” protect against SARS-CoV-2 in hamster model

Researchers in China, The Netherlands, France, and Switzerland have identified synthetic nanobodies or “sybodies” that exhibit potent neutralizing activity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.

3 Aug 2021

Flagging potential molecular predictors of response to biological therapies in ulcerative colitis

Several individuals suffering from bowel diseases like ulcerative colitis fail to respond to conventionally used biologic therapies.

3 Aug 2021

What is the potential of microphysiological systems in COVID-19 research?

In a recently published review article in the journal Drug Discovery Today, scientists have described the utility of human-based microphysiological systems MPSs in understanding the pathophysiology of SARS-CoV-2 infection and developing effective therapeutic interventions. Moreover, they have described the establishment of a global working group to synchronize recent developments around MPSs and COVID-19 research.

3 Aug 2021

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

in vitro News and Research

Penn study discovers a targetable vulnerability in clear cell renal cell carcinoma

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

SARS-CoV-2 variants and their ability to infect mice

PTEN nuclear translocation plays a key role in neuronal injury following hypoxia-ischemia

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

Tiny gel drops for the development of regenerative therapies

Research shows how SARS-CoV-2 variants are evolving towards increased furin cleavage efficiency

Cetylpyridinium chloride-containing mouthwashes shown to inhibit SARS-CoV-2 in oral cavity

Researchers develop new low-cost reproducible system for co-cultivation of cells

Research suggests potential new treatment strategy for phenylketonuria

Two monoclonal antibodies broadly neutralize SARS-CoV-2 variants of concern

Feinstein Institutes awarded $2.9 million NIH funding for polygenic embryo selection studies

Next-generation CRISPR tools and therapies improved by modified RNA guides

Inhibition of SARS-CoV-2 replication in vitro by Losartan

“Sybodies” protect against SARS-CoV-2 in hamster model

Flagging potential molecular predictors of response to biological therapies in ulcerative colitis

What is the potential of microphysiological systems in COVID-19 research?

Pfizer moves towards an oral anti-COVID-19 therapy

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News